Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 88

1.

Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.

Ebrahimi-Nik H, Michaux J, Corwin WL, Keller GL, Shcheglova T, Pak H, Coukos G, Baker BM, Mandoiu II, Bassani-Sternberg M, Srivastava PK.

JCI Insight. 2019 Jun 20;5. pii: 129152. doi: 10.1172/jci.insight.129152.

2.

Dynamically Driven Allostery in MHC Proteins: Peptide-Dependent Tuning of Class I MHC Global Flexibility.

Ayres CM, Abualrous ET, Bailey A, Abraham C, Hellman LM, Corcelli SA, NoƩ F, Elliott T, Baker BM.

Front Immunol. 2019 May 3;10:966. doi: 10.3389/fimmu.2019.00966. eCollection 2019.

3.

Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.

Hellman LM, Foley KC, Singh NK, Alonso JA, Riley TP, Devlin JR, Ayres CM, Keller GLJ, Zhang Y, Vander Kooi CW, Nishimura MI, Baker BM.

Mol Ther. 2019 Feb 6;27(2):300-313. doi: 10.1016/j.ymthe.2018.12.010. Epub 2018 Dec 14.

PMID:
30617019
4.

The intersection of affinity and specificity in the development and optimization of T cell receptor based therapeutics.

Riley TP, Baker BM.

Semin Cell Dev Biol. 2018 Dec;84:30-41. doi: 10.1016/j.semcdb.2017.10.017. Review.

PMID:
30449534
5.

T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability.

Riley TP, Hellman LM, Gee MH, Mendoza JL, Alonso JA, Foley KC, Nishimura MI, Vander Kooi CW, Garcia KC, Baker BM.

Nat Chem Biol. 2018 Oct;14(10):934-942. doi: 10.1038/s41589-018-0130-4. Epub 2018 Sep 17.

6.

Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.

Eby JM, Smith AR, Riley TP, Cosgrove C, Ankney CM, Henning SW, Paulos CM, Garrett-Mayer E, Luiten RM, Nishimura MI, Baker BM, Le Poole IC.

Pigment Cell Melanoma Res. 2019 Jan;32(1):68-78. doi: 10.1111/pcmr.12724. Epub 2018 Aug 13.

PMID:
30009548
7.

Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.

Spear TT, Wang Y, Smith TW Jr, Simms PE, Garrett-Mayer E, Hellman LM, Baker BM, Nishimura MI.

Mol Ther. 2018 Apr 4;26(4):996-1007. doi: 10.1016/j.ymthe.2018.01.015. Epub 2018 Feb 2.

8.

Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):327. doi: 10.1007/s00262-017-2102-z.

PMID:
29264697
9.

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Erratum in: Cancer Immunol Immunother. 2017 Dec 20;:.

10.

Emerging Concepts in TCR Specificity: Rationalizing and (Maybe) Predicting Outcomes.

Singh NK, Riley TP, Baker SCB, Borrman T, Weng Z, Baker BM.

J Immunol. 2017 Oct 1;199(7):2203-2213. doi: 10.4049/jimmunol.1700744. Review.

11.

Matrix degradability controls multicellularity of 3D cell migration.

Trappmann B, Baker BM, Polacheck WJ, Choi CK, Burdick JA, Chen CS.

Nat Commun. 2017 Aug 29;8(1):371. doi: 10.1038/s41467-017-00418-6.

12.

Peptide and Peptide-Dependent Motions in MHC Proteins: Immunological Implications and Biophysical Underpinnings.

Ayres CM, Corcelli SA, Baker BM.

Front Immunol. 2017 Aug 7;8:935. doi: 10.3389/fimmu.2017.00935. eCollection 2017. Review.

13.

Modeling Sequence-Dependent Peptide Fluctuations in Immunologic Recognition.

Ayres CM, Riley TP, Corcelli SA, Baker BM.

J Chem Inf Model. 2017 Aug 28;57(8):1990-1998. doi: 10.1021/acs.jcim.7b00118. Epub 2017 Jul 25.

14.

Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.

Spear TT, Wang Y, Foley KC, Murray DC, Scurti GM, Simms PE, Garrett-Mayer E, Hellman LM, Baker BM, Nishimura MI.

Cancer Immunol Immunother. 2017 Nov;66(11):1411-1424. doi: 10.1007/s00262-017-2032-9. Epub 2017 Jun 20.

15.

How an alloreactive T-cell receptor achieves peptide and MHC specificity.

Wang Y, Singh NK, Spear TT, Hellman LM, Piepenbrink KH, McMahan RH, Rosen HR, Vander Kooi CW, Nishimura MI, Baker BM.

Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4792-E4801. doi: 10.1073/pnas.1700459114. Epub 2017 Jun 1.

16.

Using Global Analysis to Extend the Accuracy and Precision of Binding Measurements with T cell Receptors and Their Peptide/MHC Ligands.

Blevins SJ, Baker BM.

Front Mol Biosci. 2017 Jan 31;4:2. doi: 10.3389/fmolb.2017.00002. eCollection 2017.

17.

ATLAS: A database linking binding affinities with structures for wild-type and mutant TCR-pMHC complexes.

Borrman T, Cimons J, Cosiano M, Purcaro M, Pierce BG, Baker BM, Weng Z.

Proteins. 2017 May;85(5):908-916. doi: 10.1002/prot.25260. Epub 2017 Feb 16.

18.

MHC Bias by T Cell Receptors: Genetic Evidence for MHC and TCR Coevolution.

Baker BM, Evavold BD.

Trends Immunol. 2017 Jan;38(1):2-4. doi: 10.1016/j.it.2016.11.003. Epub 2016 Dec 9.

19.

Differentiation alters stem cell nuclear architecture, mechanics, and mechano-sensitivity.

Heo SJ, Driscoll TP, Thorpe SD, Nerurkar NL, Baker BM, Yang MT, Chen CS, Lee DA, Mauck RL.

Elife. 2016 Nov 30;5. pii: e18207. doi: 10.7554/eLife.18207.

20.

Ligand-Driven T Cell Receptor Selection in Celiac Disease.

Singh NK, Baker BM.

Structure. 2016 Oct 4;24(10):1623-1624. doi: 10.1016/j.str.2016.09.004.

Supplemental Content

Loading ...
Support Center